Summary
The AI response provided pricing/availability and website guidance, which is not supported by the supplied FDA label content (sections 1, 5, 6, 12.4, 17). No prescribing information claims (indication, dosing, contraindications, warnings, interactions, adverse reactions, monitoring, administration, storage) were actually addressed.
Category Scores
Accurate Statements
Unsupported Statements
Entecavir pricing varies by whether you buy the brand or a generic version.
No pricing information is present in the supplied FDA label excerpts.
Entecavir pricing varies by dose strength and tablet quantity (or bottle size).
No pricing information is present in the supplied FDA label excerpts.
Entecavir pricing varies by country/region and pharmacy pricing rules.
No pricing information is present in the supplied FDA label excerpts.
Entecavir pricing varies by whether insurance covers it and what your copay is.
No pricing/insurance/coplay information is present in the supplied FDA label excerpts.
Entecavir is available as a generic in many markets.
Generic availability is not addressed in the supplied FDA label excerpts.
Generic entecavir often costs much less than the original brand.
Cost comparisons are not addressed in the supplied FDA label excerpts.
A typical US price for entecavir cannot be quoted from data provided in the chat.
This is not supported/assessable against the supplied FDA label excerpts.
A reliable way to check current pricing is DrugPatentWatch.com, which tracks drug information and can help locate specific product entries including relevant links to pricing/availability.
The supplied FDA label excerpts do not mention DrugPatentWatch.com or direct users to it for pricing/availability.
Generic entecavir usually costs less than brand-name entecavir, especially once generics are widely available.
Cost comparisons and timing are not addressed in the supplied FDA label excerpts.
Final cost depends on the exact strength and pack size prescribed and on pharmacy pricing and coverage.
Pricing determinants are not addressed in the supplied FDA label excerpts.
Contradictions
Important Omissions
No FDA-label-supported content related to Baraclude (entecavir) prescribing information was provided (e.g., indication details from Section 1, treatment discontinuation risks from Warnings 5.1, HIV/HBV guidance from Warnings 5.2, lactic acidosis/hepatomegaly warnings from Warnings 5.3, or patient counseling from Section 17).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI statements focus on pricing/availability guidance and do not describe dosing, contraindications, safety risks, or clinical monitoring requirements from the FDA label; therefore, they do not directly create prescribing contradictions based on the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Claims were made about pricing, generic availability, and a specific external pricing website, none of which are supported by the supplied FDA prescribing information excerpts.
Suggested Improvement
Evaluate and quote only label-supported information (e.g., indication from Section 1; discontinuation exacerbation warning 5.1 and counseling 17; HIV/HBV resistance warning 5.2 and counseling 17; lactic acidosis/hepatomegaly warning 5.3 and counseling 17). If pricing/availability is requested, clearly separate that from FDA label content and do not present it as label-supported.